Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -19.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-9.8%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 68.6% higher than minimum and 8.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (46.8x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+2.2%)223.43
year average price 207.53  


year start price 190.77 2025-02-08

min close price 170.16 2025-04-21

max close price 244.38 2025-10-01

current price 223.43 2026-02-07
Common stocks: 1 768 480 508

Dividend Yield:  3.0%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 46.8x
EV / EBITDA annualized: 54.7x
Last revenue growth (y/y):  +9.1%
Last growth of EBITDA (y/y):  -47.9%
Historical revenue growth:  +1.2%
Historical growth of EBITDA:  -20.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 395 132
Net Debt ($m): 63 115
EV (Enterprise Value): 458 247
EBITDA LTM ($m): 9 787
EV / LTM EBITDA: 46.8x
Price to Book: -149.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-05marketbeat.com

AbbVie's Prognosis: The February Dip Looks Like a Buy Signal

2026-02-05seekingalpha.com

AbbVie: The Market Is Getting It Wrong

2026-02-05seekingalpha.com

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

2026-02-04seekingalpha.com

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

2026-02-04seekingalpha.com

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

2026-02-04zacks.com

AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View

2026-02-04zacks.com

AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

2026-02-04prnewswire.com

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

2026-02-03prnewswire.com

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

2026-02-02zacks.com

Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data